Borse Rebekah H, Shrestha Sundar S, Fiore Anthony E, Atkins Charisma Y, Singleton James A, Furlow Carolyn, Meltzer Martin I
Centers for Disease Control and Prevention, Atlanta, GA 30333, USA
Emerg Infect Dis. 2013 Mar;19(3):439-48. doi: 10.3201/eid1903.120394.
In April 2009, the United States began a response to the emergence of a pandemic influenza virus strain: A(H1N1)pdm09. Vaccination began in October 2009. By using US surveillance data (April 12, 2009-April 10, 2010) and vaccine coverage estimates (October 3, 2009-April 18, 2010), we estimated that the A(H1N1)pdm09 virus vaccination program prevented 700,000-1,500,000 clinical cases, 4,000-10,000 hospitalizations, and 200-500 deaths. We found that the national health effects were greatly influenced by the timing of vaccine administration and the effectiveness of the vaccine. We estimated that recommendations for priority vaccination of targeted priority groups were not inferior to other vaccination prioritization strategies. These results emphasize the need for relevant surveillance data to facilitate a rapid evaluation of vaccine recommendations and effects.
2009年4月,美国开始应对一种大流行性流感病毒株的出现:甲型(H1N1)pdm09。2009年10月开始接种疫苗。利用美国监测数据(2009年4月12日至2010年4月10日)和疫苗接种覆盖率估计值(2009年10月3日至2010年4月18日),我们估计甲型(H1N1)pdm09病毒疫苗接种计划预防了70万至150万例临床病例、4000至10000例住院治疗以及200至500例死亡。我们发现,国家健康影响在很大程度上受到疫苗接种时间和疫苗效力的影响。我们估计,针对目标优先群体的优先接种建议并不逊色于其他疫苗接种优先策略。这些结果强调了相关监测数据对于快速评估疫苗建议和效果的必要性。